Intracameral moxifloxacin for endophthalmitis prophylaxis after cataract surgery: Cost-effectiveness analysis
Journal of Cataract & Refractive Surgery Jul 26, 2018
Leung EH, et al. - Researchers ascertained the cost-effectiveness of intracameral moxifloxacin compared with traditional antibiotic prophylaxis in preventing endophthalmitis after cataract surgery. From a societal perspective in the US, findings suggested cost-efficacy of a topical perioperative antibiotic with a 500 g intracameral moxifloxacin costing $22 dollars or less. This treatment module was also seen to be cost-saving. A $20 intracameral moxifloxacin, from a healthcare sector perspective was cost-effective but not cost-saving. Greater effectiveness in improving quality-adjusted-life-years (QALYs) was demonstrated by adjuvant intracameral moxifloxacin vs topical antibiotics.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries